Detection of preclinical parkinson disease in at-risk family members with use of [123I]-CIT and SPECT: An exploratory study

Mayo Clinic Proceedings

Volumn 74, Issue 7, 1999, Pages 681-685

  Maraganore, Demetrius M ^a,b   O'Connor, Michael K ^a   Bower, James H ^a,b   Kuntz, Karen M ^a   Mcüonnell, Shannon K ^a   Schah, Daniel J ^a   Rocca, Walter A ^a  

^a Department of Neurology ^*  (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 123; RADIOLIGAND;

ARTICLE; BRAIN MAPPING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HIGH RISK POPULATION; HUMAN; PARKINSON DISEASE; RELATIVE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0032989409     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.7.681     Document Type: Article

References (12)

1. Piccini P, Morrish PK, Turjanski N, et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron émission tomography study. Ann Neural. 1997;41:222-229.
2. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I]-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemiParkinson's disease. Neurology. 1996;46:231-237.
3. Semchuk KM, Love El, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology. 1993;43:1173-1180.
4. de Rijk MC, Breteler MMB, van der Mèche FGA, Hofman A. The risk of Parkinson's disease among persons with a family history of Parkinson's disease or dementia: the Rotterdam study [abstract]. Neurology. 1997;48(suppl 2):A333-A334.
5. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neural Neurosurg Psychiatry. 1988;51:745-752.
6. Kokmen E, Naessens JM, Offord KP. A short test of mental status: description and preliminary results. Mayo Clin Proc. 1987;62:281288.
7. Tukey JW. Exploratory Data Analysis. Reading, Mass: AddisonWesley Publishing Co; 1977.
8. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology. 1999;52:1214-1220.
9. Nemetz PN, Ballard DJ, Beard CM, et al. An anatomy of the autopsy, Olmsted County, 1935 through 1985. Mayo Clin Proc. 1989;64:1055-1064.
10. Ellenberg JH. Preclinical markers in studies of Parkinson's disease. Geriatrics. 1991;46(suppl l):16-24.
11. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. JNeural Neurosurg Psychiatry. 1998:64:314-319.
12. Joyce JN, Smutzer G, Whitty CJ, Myers A, Bannen MJ. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Mov Disord. 1997; 12:885-897.